|本期目录/Table of Contents|

[1]魏诗瑶,来佳丹,李常颖.白细胞介素4诱导蛋白1促进肾癌进展的实验研究[J].天津医科大学学报,2022,28(04):366-371.
　WEI Shi-yao,LAI Jia-dan,LI Chang-ying.Research of interleukin-4-induced-1 promoting the progression of kidney clear cell carcinoma[J].Journal of Tianjin Medical University,2022,28(04):366-371.
点击复制

白细胞介素4诱导蛋白1促进肾癌进展的实验研究(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
28卷
期数:
2022年04期
页码:
366-371
栏目:
基础医学
出版日期:
2022-07-20

文章信息/Info

Title:
Research of interleukin-4-induced-1 promoting the progression of kidney clear cell carcinoma
文章编号:
1006-8147（2022）04-0366-06
作者:
魏诗瑶; 来佳丹; 李常颖
（天津医科大学第二医院泌尿外科，天津市泌尿外科研究所，天津300211）
Author(s):
WEI Shi-yao; LAI Jia-dan; LI Chang-ying
（Department of Urology，Tianjin Institute of Urology，The Second Hospital，Tianjin Medical University，Tianjin 300211，China）
关键词:
IL4I1; 肾透明细胞癌; 预后; 增殖; 迁移
Keywords:
IL4I1;  kidney clear cell carcinoma;  prognosis;  proliferation;  migration
分类号:
R737.11
DOI:
-
文献标志码:
A
摘要:
目的：探讨白细胞介素4诱导蛋白1（IL4I1）在肾透明细胞癌中的表达及在肿瘤发展中的作用。方法：通过数据库分析IL4I1在正常肾组织和肾透明细胞癌组织中的表达及与预后的关系；通过qPCR和FCM比较正常肾细胞HK-2与肾癌细胞系786-O和769-P中IL4I1的表达情况；siRNA干扰786-O细胞系IL4I1表达后通过CFSE增殖实验及细胞划痕实验探究细胞生物学行为的改变；通过GSEA分析和qPCR探究潜在机制。结果：IL4I1在肾透明细胞癌组织中过表达（P＜0.001），提示更短的总生存期（P＜0.001）。IL4I1在肾癌细胞系786-O中mRNA及蛋白水平均过表达（t=16.83、280.40，均P＜0.001）。干扰IL4I1表达后，786-O细胞增殖速度减慢，迁移能力下降（F=97.45，P＜0.001），并伴随细胞间黏附分子-1（ICAM1）、血管内皮生长因子A （VEGFa）、基质金属蛋白酶9（MMP9）、程序性细胞死亡蛋白-1（PD-L1）表达水平降低（t=9.031、8.613、9.066、12.66，均P＜0.05）。GSEA分析显示，在IL4I1高表达的肾透明细胞癌组中，存在细胞周期、P53信号通路、细胞间黏附分子及VEGF信号通路的富集（FDR＜0.25，P＜0.05）。结论：IL4I1在肾癌中高表达且与患者不良预后正相关；IL4I1促进肾癌细胞的增殖和迁移。
Abstract:
Objective: To explore the expression and roles of interleukin-4-induced-1 （IL4I1） in kidney clear cell carcinoma （KIRC）. Methods: Online database was used to analyze the expression of IL4I1 between normal kidney tissue and KIRC，and the influence of IL4I1 in tumor prognosis. Expression of IL4I1 between normal kidney cell line HK-2 and KIRC cell line 786-O and 769-P was verified by qPCR and FCM in KIRC cell lines. The siRNA was used to silence the IL4I1 expression in 786-O cell line. Cell proliferation and migration were measured by CFSE proliferation assay and the wound healing assay. Potential mechanism was predicated by GSEA analysis and qPCR. Results: IL4I1 was over-expressed in KIRC（P<0.001） and indicated a shorter overall survival（P<0.001）. IL4I1 was also significantly over-expressed in 786-O cell line in mRNA and protein level（t=16.83，280.40，all P<0.001）. After IL4I1 silence，the proliferation rate and migration ability of 786-O cell line were significantly decreased（F=97.45，P<0.001），accompanied by decreased expression of intercellular cell adhesion molecule-1 （ICAM1），vascular endothelial growth factor A （VEGFa），matrix metallopeptidase 9 （MMP9） and programmed death-1（PD-L1）（t=9.031，8.613，9.066，12.66，all P<0.05）. GSEA analysis showed the enrichment of cell cycle，P53 signaling pathway，cell adhesion molecules （CAMs），and VEGF signaling pathway in KIRC group which had a higher IL4I1 expression level （FDR<0.25，P<0.05）. Conclusion: IL4I1 is highly expressed in KIRC and positively correlated with poor prognosis. IL4I1 promotes the proliferation and migration of renal cancer cells.

参考文献/References:

[1] BOD L，LENGAGNE R，WROBEL L，et al. IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma[J]. Onco Immunol，2017，6（3）：e1278331.
[2] SADIK A，SOMARRIBAS PATTERSON L F，?魻ZT?譈RK S，et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression[J].Cell，2020，182（5）：1252-1270.
[3] MOLINIER-FRENKEL V，PR?魪VOST-BLONDEL A，CASTELLANO F. The IL4I1 enzyme：a new player in the immunosuppressive tumor microenvironment[J].Cells，2019，8（7）：757.
[4] CAMPBELL S，UZZO R G，ALLAF M E，et al. Renal mass and localized renal cancer：AUA guideline[J]. J Urol，2017，198（3）：520-529.
[5] EAU Guidelines： Renal cell carcinoma | Uroweb[EB/OL]. [2021/12/23]. https：//uroweb.org/guideline/renal-cell-carcinoma/.
[6] WISHART D S. Is cancer a genetic disease or a metabolic disease?[J]. EBioMedicine，2015，2（6）：478-479.
[7] FDA APPROVES NEW TARGETED TREATMENT FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA | FDA[EB/OL]. [2021/12/23]. https：//www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-relapsed-or-refractory-acute-myeloid-leukemia.
[8] SUDARSHAN S，KARAM J A，BRUGAROLAS J，et al. Metabolism of kidney cancer：from the lab to clinical practice[J]. Eur Urol，2013，63（2）：244-251.
[9] BOULLAND M，MARQUET J，MOLINIER-FRENKEL V，et al. Human IL4I1 is a secreted l-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation[J].Blood，2007，110（1）：220-227.
[10] PUIFFE M L，DUPONT A，SAKO N，et al. IL4I1 accelerates the expansion of effector CD8（+） T cells at the expense of memory precursors by increasing the threshold of T-cell activation[J]. Front Immunol，2020，11：600012.
[11] AUBATIN A，SAKO N，DECROUY X，et al. IL4-induced gene 1 is secreted at the immune synapse and modulates TCR activation independently of its enzymatic activity[J]. Eur J Immunol，2018，48（1）：106-119.
[12] RAMSPOTT J P，BEKKAT F，BOD L，et al. Emerging role of IL-4-Induced gene 1 as a prognostic biomarker affecting the local T-cell response in human cutaneous melanoma[J]. J Invest Dermatol，2018，138（12）：2625-2634.
[13] COUSIN C，AUBATIN A，LE GOUVELLO S，et al. The immunosuppressive enzyme IL4I1 promotes FoxP3（+） regulatory T lymphocyte differentiation[J]. Eur J Immunol，2015，45（6）：1772-1782.
[14] GAO Y，SHANG W，ZHANG D，et al. Lnc-C/EBPβ modulates differentiation of MDSCs through downregulating IL4i1 with C/EBPβ LIP and WDR5[J]. Front Immunol，2019，10：1661.
[15] ZHAO H，TENG Y，HAO W，et al. Single-cell analysis revealed that IL4I1 promoted ovarian cancer progression[J]. J Transl Med，2021，19（1）：454.
[16] 庄敏敏，张云艳. ICAM-1在肿瘤中的研究进展[J].实用肿瘤学杂志，2018，32（1）：82-86.
[17] CLAESSON-WELSH L，WELSH M. VEGFA and tumour angiogenesis[J]. J Intern Med，2013，273（2）：114-127.
[18] HUANG H. Matrix Metalloproteinase-9（MMP-9） as a cancer biomarker and MMP-9 biosensors：recent advances[J]. Sensors（Basel），2018，18（10）：3249.
[19] MACKINNON A，BHUPATHI D，CHEN J，et al. 705 Anti-tumor activity of CB-668，a potent，selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme interleukin 4 （IL-4）-induced gene 1（IL4I1）[J]. J Immunother Cancer，2020，8（Suppl 3）：A423.
[20] PRESSET M，DJORDJEVIC D，DUPONT A，et al. Identification of inhibitors of the immunosuppressive enzyme IL4I1[J]. Bioorganic Chemistry，2020，94：103463.

相似文献/References:

[1]张春锋,李长建,刘沛,等.KIF22在肾透明细胞癌中的表达及临床相关性研究[J].天津医科大学学报,2023,29(03):309.
　ZHANG Chun-feng,LI Chang-Jian,LIU Pei,et al.Expression and clinical correlation of KIF22 in clear cell renal cell carcinoma[J].Journal of Tianjin Medical University,2023,29(04):309.
[2]刘芬,李世宾,李晓石.人着丝粒蛋白E在人肾透明细胞癌中的表达及对细胞增殖的影响[J].天津医科大学学报,2023,29(06):594.
　LIU Fen,LI Shi-bin,LI Xiao-shi.Expression of human centromere protein E in human renal clear cell carcinoma and its effects on the cell proliferation[J].Journal of Tianjin Medical University,2023,29(04):594.
[3]来佳丹,魏诗瑶,李常颖.肾癌来源的IL4I1介导Treg诱导与募集的实验研究[J].天津医科大学学报,2023,29(03):302.
　LAI Jia-dan,WEI Shi-yao,LI Chang-ying.Research on inducement and recruitment of Treg mediated by IL4I1 derived from renal cell carcinoma[J].Journal of Tianjin Medical University,2023,29(04):302.
[4]李美,来佳丹,魏诗瑶,等.肾透明细胞癌来源的IL4I1介导PD1+CD8+ T淋巴细胞募集的相关研究[J].天津医科大学学报,2024,30(02):122.[doi:10.20135/j.issn.1006-8147.2024.02.0122]
　LI Mei,LAI Jiadan,WEI Shiyao,et al.Research on recruitment of PD1+ CD8+ T lymphocytes mediated by IL4I1 derived from clear cell renal cell carcinoma[J].Journal of Tianjin Medical University,2024,30(04):122.[doi:10.20135/j.issn.1006-8147.2024.02.0122]

备注/Memo

备注/Memo:
基金项目 天津市自然科学基金（16JCYBJC26500）
作者简介: 魏诗瑶（1996-），女，硕士在读，研究方向：泌尿系统肿瘤微环境；通信作者：李常颖，E-mail:cli_cvrl@tmu.edu.cn。
更新日期/Last Update: 2022-07-20